Capital Raising

OPEN

Biosignals Diagnostics

Precision Health, Cardiac Diagnostics, Remote Patient Monitoring (Primary Care)

I am interested

INDUSTRY

Medical & Healthcare

RAISING

$4M

PRE-MONEY VALUATION

$35M

MINIMUM INVESTMENT

$50,000

Investment Highlights

Transaction Overview

Traction / Milestones

Company Overview

Revenue Model

Why Now?

Products & Services

Team

Announcements

Transaction Summary
Biosignals Diagnostics

Raising: $4M

Pre-Money Valuation: $35M

Minimum Investment $50,000

Request Further Information

Investment Highlights

AI-powered longitudinal diagnostics

mapdx™ creates longitudinal patient models rather than analysing isolated events, enabling diagnostics that consider medication profiles, disease progression and patient history.

Three revenue pillars 
Designed to create recurring revenue and scalable software economics: Diagnostic Services, Data Acquisition Devices and Platform Licensing

Existing commercial infrastructure

  • ecgme® TGA registered
  • ecgme® CE marked
  • National Chemist Warehouse distribution agreement in place
  • Best Practice Software integration delivered
  • Cardiologist network activation in progress

Expandable platform architecture

The mapdx™ platform architecture is designed to extend to additional clinical monitoring domains over time. Specific expansion sectors will be confirmed as development and regulatory pathways mature.

Large addressable market

Management estimates a serviceable Australian revenue opportunity exceeding $71 million by 2031 as the platform scales across cardiac and adjacent monitoring sectors. This is a forward-looking estimate dependent on clinical, regulatory and commercial execution.

Transaction Overview

Terms of offer:

Biosignals Diagnostics Pty Ltd is seeking:

  • Raise Amount: $4 million 
  • Pre-Money Valuation: $35 million
  • Share Price: $0.562 per share
  • Equity offered: 10.26%
  • Minimum Investment: $50,000
  • Security: Ordinary shares

USE OF FUNDS

mapdx™ Platform Development

ecgme® Manufacturing and Marketing

Clinical Node Activation

Transporter Development

40%
Fill Counter
17.5%
Fill Counter
30%
Fill Counter
12.5%
Fill Counter

Traction / Milestones

Regulatory

  • ecgme® TGA registered
  • ecgme® CE marked

Commercial

  • National Chemist Warehouse distribution agreement in place
  • Direct-to-consumer sales channel active

Clinical

  • Best Practice Software integration delivered
  • Cardiologist partnership agreements progressing
  • Distributed specialist node model commencing

Market Validation

  • HealthEd Conference Champion 2024
  • 600 GPs independently rated ecgme®

Company Overview

BiosignalsDx is building a longitudinal diagnostic monitoring platform that combines AI-enabled diagnostics, distributed specialist networks, and context-aware patient monitoring to identify disease earlier and improve clinical decision-making.

BiosignalsDx aims to close the gap between when disease begins and when it is detected. Through its mapdx™ platform, cardiologist-led clinical network and regulated diagnostic devices, the company is creating a new model of longitudinal healthcare monitoring that incorporates patient history, medications, disease progression and real-world clinical context. The platform is initially focused on cardiovascular monitoring, with an architecture designed to extend to further clinical monitoring domains as development and regulatory pathways mature.

Revenue Model

Diagnostic Services

Recurring fee-for-service diagnostic monitoring delivered through BiosignalsDx's specialist clinical network. Current focus: Remote Patient Monitoring and Mobile Cardiac Telemetry.

Data Acquisition

Revenue generated from ecgme® device sales, device leasing, consumables, and future multi-lead cardiac telemetry hardware.

Platform Licensing

High-margin recurring revenue opportunities through clinical platform licensing, per-node licensing, clinical intelligence reporting, and pharmaceutical data licensing.

Why Now?

  • ecgme® TGA and CE regulatory approvals secured.
  • The mapdx™ platform is in development; the software-as-a-medical-device regulatory pathway is being planned.
  • Commercial infrastructure is already established.
  • National Chemist Warehouse distribution agreement in place.
  • Best Practice Software integration delivered.
  • Specialist cardiology node network commencing.
  • mapdx™ platform development accelerating.
  • Capital raising is focused on deployment rather than concept validation.
  • International expansion pathway. Following completion of the current raise, BiosignalsDx intends to progress international market-access and holding-structure planning for Asian markets, supported by government investment-facilitation channels.

Previous Funding

Biosignals Diagnostics has been funded through prior shareholder rounds totalling A$1,800,000 from 2020 to 2026, delivering the ecgme® product line, establishing clinical service readiness, and progressing the mapdx™ platform and multi-lead cardiac telemetry development milestones.

Products & Services

 

  1. ecgme® handheld ECG monitor, single-lead capture configurable up to 10 minutes, plus side electrode enabling captures at standard anatomical positions, and an on-body adaptor enabling continuous monitoring.
  2. Mobile app (iOS and Android), enabling capture, storage, and sharing of results, with clinic-ready workflow integration.
  3. Cardiologist review services (optional paid reviews for arrhythmia and ischaemia, plus HRV).
  4. mapdx™ AI-enabled longitudinal diagnostic platform, with clinic and customer portals, clinical workflow integration, and a decision-support roadmap.
  5. Holter and Holter Plus service model for general practice, designed to reduce access delays and improve turnaround in remote and rural settings.
  6. Multi-lead cardiac telemetry system in development, extending the platform beyond single-lead capture. Roadmap and timing subject to funding.

Team

  • Management

Richard Rendell

CEO & Managing Director                   

A/Prof Stephen Foy

Cardiologist & Non-Executive Director   

Yuhong (Lexie) Qin

Advisor &              Co-Founder 

Dr David Urpani

AI & Machine Learning              

A/Prof Cheng-Hon Yap

Adviser    

Dr Ramanathan Parameswaran

Adviser 

Dr David Page

Adviser                           

Announcements

 October 2025

Biosignals Diagnostics partners with Australia's leading GP software provider   

General Disclaimer

The content on this site is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security and is not warranted to be correct, complete or accurate. This site is intended for Accredited/Sophisticated/Wholesale investors only. By continuing with an investment, you are self-accrediting that you so qualify. To the extent permitted by law, neither PrimaryMarkets, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment opportunities on this site and any statements made about them by their issuers are not vetted or verified by PrimaryMarkets. Investing in securities in private or unlisted companies and Funds is speculative and involves a high degree of risk. The investor must be prepared to withstand a total loss of their investment. We strongly encourage the investor to seek independent financial, professional or investment advice before investing in securities. The presence of an investment opportunities on this site should not be interpreted as an implied endorsement of it by PrimaryMarkets. Some content provided may constitute a summary or extract of another document. Past performance does not necessarily indicate future performance. The content on this site was current as at date of initial publication but may not be current as at the date of your viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.

Want to learn more?

Fill in the expression of interest form below